Skinvisible, Inc. (SKVI)
OTCMKTS
· Delayed Price · Currency is USD
0.1052
-0.0641 (-37.86%)
Jun 27, 2025, 3:08 PM EDT
Skinvisible Revenue
Skinvisible had revenue of $5.00K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $20.00K. In the year 2024, Skinvisible had annual revenue of $20.00K.
Revenue
20.00K
Revenue Growth
n/a
P/S Ratio
72.14
Revenue / Employee
10.00K
Employees
2
Market Cap
1.44M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.00K | - | - |
Dec 31, 2023 | 20.00K | -259.30K | -92.84% |
Dec 31, 2022 | 279.30K | -384.13K | -57.90% |
Dec 31, 2021 | 663.43K | 387.87K | 140.76% |
Dec 31, 2020 | 275.56K | 232.39K | 538.36% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cordyceps Sunshine Biotech Holdings | 1.25M |
Cuisine Solutions | 80.48M |
Armanino Foods of Distinction | 69.40M |
South Dakota Soybean Processors, LLC | 524.07M |
ESG Inc. | 11.89M |
Pyxus International | 2.48B |
Crimson Wine Group | 71.52M |
Hi-Great Group Holding Company | 69.04K |
Skinvisible News
- 5 months ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 5 months ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 9 months ago - Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development - Accesswire
- 1 year ago - Promising Data on Transdermal Obesity Formulations Announced by Skinvisible - Accesswire
- 1 year ago - Skinvisible Expands Obesity Patent Application for Transdermal Delivery - Accesswire
- 1 year ago - Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome - Accesswire
- 3 years ago - Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug - Accesswire